Two Hopefuls And A ‘No’: EMA Decisions On Accelerated Access

 
• By Neena Brizmohun

Regeneron and Shire should find out this week whether the European Medicines Agency will agree to fast-track its review of their products.

Hands writing on a paper
Two applications for fast-review will be considered at this month's CHMP meeting

More from Product Reviews

More from Pink Sheet